Prostate Cell News Volume 8.39 | Oct 13 2017

TOP STORY

Androgen Receptor Pathway-Independent Prostate Cancer Is Sustained through FGF Signaling

Scientists found that pharmacological inhibitors of MAPK or FGFR repressed the growth of double-negative prostate carcinomas in vitro and in vivo. Their results indicated that FGF/MAPK blockade may be particularly efficacious against metastatic prostate cancer with an androgen receptor-null phenotype. [Cancer Cell] Full Article

(Ranked by impact factor of the journal)

Selective Neutralization of IL-12 p40 Monomer Induces Death in Prostate Cancer Cells Via IL-12–IFN-γ

Researchers found that different mouse and human cancer cells produced greater levels of IL-12 p40 monomer (p40) than p40 homodimer, IL-12, or IL-23. Similarly, the serum level of p40 was much greater in patients with prostate cancer than in healthy control subjects. [Proc Natl Acad Sci USA] Abstract

DHX15 Promotes Prostate Cancer Progression by Stimulating Siah2-Mediated Ubiquitination of Androgen Receptor

Investigators identified the RNA helicase DHX15 as a novel androgen receptor (AR) co-activator using a yeast mutagenesis screen and revealed that DHX15 regulates AR activity by modulating E3 ligase Siah2-mediated AR ubiquitination independent of its ATPase activity. [Oncogene] Abstract

Ligand-Dependent EphA7 Signaling Inhibits Prostate Tumor Growth and Progression

To test the role of EphA7 receptor in prostate cancer progression directly, researchers generated EphA7 receptor variants that were either lacking the cytoplasmic domain or carrying a point mutation that inhibits its phosphorylation by site-directed mutagenesis. [Cell Death Dis] Full Article

Elevated Expression of Par3 Promotes Prostate Cancer Metastasis by Forming a Par3/aPKC/KIBRA Complex and Inactivating the Hippo Pathway

Researchers found that elevated expression of Par3 was positively associated with prostate cancer (PCa) metastasis. Knockdown of Par3 inhibited PCa cell migration and invasion in vitro and tumor metastasis in vivo, whereas overexpression of Par3 yielded the opposite results. [J Exp Clin Cancer Res] Full Article

Loss of ABHD5 Promotes the Aggressiveness of Prostate Cancer Cells

Investigators demonstrated that RNAi-mediated alpha-beta hydrolase domain containing 5 (ABHD5) silencing promotes, whereas ectopic ABHD5 overexpression inhibits, the invasion and proliferation of prostate cancer cells. [Sci Rep] Full Article

LincRNA-p21 Suppresses Development of Human Prostate Cancer through Inhibition of PKM2

Scientists revealed that long intergenic non-coding RNA-p21 (lincRNA-p21) silencing in DU145 and LNCaP cells induced up-regulation of PKM2 and activation of glycolysis, which could be reversed by PKM2 knockdown or rapamycin treatment. [Cell Prolif] Abstract

Establishment of a Dog Primary Prostate Cancer Organoid Using the Urine Cancer Stem Cells

Researchers generated prostate cancer organoids using dog urine samples. Each organoid showed cystic structures and resembled the epithelial structures of original tissues. Expression of an epithelial cell marker, E-cadherin and a myofibloblast marker, α-SMA was observed in the urine organoids. [Cancer Sci] Abstract

Targeting MTA1/HIF-1α Signaling by Pterostilbene in Combination with Histone Deacetylase Inhibitor Attenuates Prostate Cancer Progression

The authors generated and utilized a luciferase reporter in a prostate-specific Pten-null mouse model to evaluate the anticancer efficacy of pterostilbene/SAHA combinatorial approach. [Cancer Med] Full Article

Natriuretic Peptides: The Case of Prostate Cancer

Scientists summarize the current knowledge on the link between prostate cancer and inflammation and the potential use of natriuretic peptides as anti-inflammatory and anticancer agents. [Molecules] Full Article

Visit our reviews page to see a complete list of reviews in the prostate cell research field.

Janssen Submits New Drug Application to U.S. FDA for Apalutamide (ARN-509) to Treat Men with Non-Metastatic Castration-Resistant Prostate Cancer

Janssen Biotech, Inc. announced that it has submitted a New Drug Application to the FDA for apalutamide, an investigational, next generation oral androgen receptor inhibitor for men with non-metastatic castration-resistant prostate cancer. [Janssen Biotech, Inc.] Press Release

Siamab Therapeutics and Boehringer Ingelheim Announce Strategic Cancer Immunology Discovery Collaboration to Develop Antibody Therapeutics Targeting Multiple Solid Tumors

Siamab Therapeutics, Inc. and Boehringer Ingelheim announced that they have entered into a strategic discovery collaboration with the goal of developing anti-cancer therapeutics targeting tumor associated carbohydrate antigens. [Siamab Therapeutics, Inc. (Business Wire, Inc.)] Press Release

NSF Drops Preproposals, Deadlines for Biologists Seeking Funding

The National Science Foundation (NSF) will no longer require biologists applying for grants to submit preproposals and to adhere to an annual deadline for submissions. The changes pull the plug on a five-year pilot project in two NSF divisions—and mark the agency’s latest attempt to reduce the burden of the grant review system on its staff and outside researchers without lowering its standards. [ScienceInsider] Editorial

South African Researchers Bemoan Slashed Funds

Academics in South Africa are in uproar after a government research agency announced plans to cut the budget of a prestigious grant program that rewards the country’s best researchers. [Nature News] Editorial

European Drug Regulation at Risk of Stalling as Agency Prepares to Leave London

Drug regulation in Europe could temporarily freeze if the European Medicines Agency loses staff during its post-Brexit move from London. Up to 70 per cent of its 900 staff have said they would quit if the agency relocated to some of the cities bidding to host the organization. [Nature News] Editorial

NEW Keystone Symposia: Precision Medicine in Cancer
May 6-10, 2018
Stockholm, Sweden

Visit our events page to see a complete list of events in the community.

NEW Postdoctoral Scientist – Prostate Oncobiology (CRUK Manchester Institute)

NEW Postdoctoral Position – Cancer Biology (The Henry Ford Health System)

Research Fellow – Prostate Cancer (Norwegian University of Science and Technology)

Doctoral Student – Prostate Cancer (Lund University)

Director – Stanford Cancer Institute (Stanford University)

Postdoctoral Position – Cancer Biology and Epigenetics (Duke University)

Researcher – Cancer Biology (University of Cincinnati)

Postdoctoral Position – Prostate Cancer (Baylor College of Medicine)

Postdoctoral Position – Prostate Related Diseases (Baylor College of Medicine)

Postdoctoral Fellow – Drug Discovery (Vancouver Prostate Centre)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here.